by Admin | Jun 5, 2019 | Delos News
PHOENIX – June 5, 2019 – OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company founded on the myxoma virus (MYXV) platform from Arizona State University (ASU), announced today the completion of a $25 million series A financing led by Boehringer...
